Trial Profile

A Phase 2, Open-Label, Cross-over Study to Assess the Safety and Efficacy of Avexitide in Acquired Hyperinsulinemic Hypoglycemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avexitide (Primary)
Indications Hyperinsulinaemia
Focus Therapeutic Use

Most Recent Events

17 Aug 2022 Status changed from recruiting to completed.
13 Jun 2022 According to an Eiger BioPharmaceuticals media release, Primary endpoint (Number of diurnal Level 2 hypoglycemia events (ADA, 54 mg/dL) as measured by CGM in patients with severe HH) has been met.
13 Jun 2022 Results presented in an Eiger BioPharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com